Regeneron posts fourth-quarter win as COVID therapy moderates Eyle (NASDAQ:REGN)

Quarterly results


Regeneron Pharmaceuticals (NASDAQ: VLAD) beat Street forecasts with its fourth-quarter 2022 financials on Friday as the company posted better-than-expected sales for its antibody therapy for COVID-19 REGEN-COV despite poor results from its breakthrough eye therapy Eyle.


Source link

Leave a Reply

Your email address will not be published. Required fields are marked *